Immunotherapy as a treatment for small cell lung cancer: a case report and brief review.

Small cell lung cancer (SCLC), an aggressive disease characterized by rapid progression, early relapse and widespread metastasis, accounts for about 13-15% of lung cancer cases. Despite its initial sensitivity to chemotherapy and radiotherapy, SCLC commonly develops resistance to these treatments and, as such, has high recurrence rates. In recent years, immunotherapy has shown promising antitumor activity and the approach to tumor treatment has been changed, in particular, by programmed death receptor-1/ligand 1 (PD-1/L1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) checkpoint inhibitors. SCLC has high immunogenicity, a high mutation burden, and other favorable immune factors, meaning immune checkpoint inhibitors (ICIs) could become a breakthrough in the treatment of SCLC. In our case report, we found that ICIs resulted in partial response (PR), and in our review, we focused on clinical trials of immunotherapy, especially in relation to ICIs in SCLC. 2020 Translational Lung Cancer Research. All rights reserved.

Introduction

Small cell lung cancer (SCLC) accounts for about 15% of all lung cancer cases (1). It is an aggressive disease, characterized by the extensive spread of early metastasis. According to the International Association for Lung Cancer Research (IASLC) standard ‘TNM’ staging, SCLC can be classified into 2 stages: limited stage (LS-SCLC) and extended stage (ES-SCLC). Approximately 70% of SCLC patients are classified as having ES-SCLC (2,3).

The standard initial treatment for advanced ES-SCLC is platinum-based chemotherapy, which has a high response rate (RR) but a transient response overall (4,5). Patients whose tumors recur more than 6 months after first-line chemotherapy can benefit from repeated treatment using the same original regimen (6). Topotecan, with a RR of 15–20% and a 1-year overall survival (OS) rate of 30%, is the second-line treatment for SCLC (7). The options for subsequent lines of treatment are limited, meaning there is an urgent demand for new treatments for patients with SCLC. The majority of SCLC patients are characterized by smoking exposure, high tumor mutational burden (TMB), and high neoantigens formation, all of which may impact the effectiveness of immunotherapy.

At present, studies have been conducted on the two immune checkpoint inhibitor (ICI) pathways—programmed death receptor-1/ligand 1 (PD-1/L1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4)—as well as combined therapy for the two pathways. In the studies conducted to date, immunotherapy has been shown to have positive effects as part of the treatment of SCLC patients. Results of IMPOWER-133, for example, showed a longer progression-free survival (PFS) and OS in patients receiving etoposide/carboplatin/atezolizumab (8). Subsequently, many clinical studies in which immunotherapy is combined with chemotherapy as the first-line treatment of SCLC, such as the CASPIAN study, are ongoing. In our case report, we observed a patient treated with chemotherapy combined with immunotherapy who achieved partial response (PR), and then subsequently conducted a review of studies which have focused on the role of ICIs in SCLC.

Case presentation

On September 27, 2018, a 68-year-old man was admitted to Shanghai Pulmonary Hospital for 1 week, suffering from a cough, chest tightness, and asthma. He had smoked one pack per day for 40 years. A physical examination discovered that one of the patient’s right neck lymph nodes was enlarged. A CT scan of the patient’s chest revealed a mass in the left lung, enlarged mediastinal and left hilum lymph nodes, and left pleural effusion (). The biopsy pathology of the patient’s right neck lymph node showed metastatic neuroendocrine carcinoma, SCLC. Immunohistochemistry studies showed expression of CD56, CgA positive (weak) staining, and synaptophysin, CK negative staining. We also stained for PD-1, PD-L1, and CD8+ (). Magnetic resonance imaging (MRI) of the patient’s brain revealed no evidence of metastatic disease. The patient was diagnosed with left lung SCLC T2N2M1-Stage IV (right neck lymph node, left pleural effusion) (IASLC 8th Edition) and received treatment with PD-L1 inhibitor plus etoposide plus carboplatin (PD-L1 inhibitor: every 3 weeks on day 1; carboplatin: AUC 5 on day 1; etoposide: 100 mg/m2 on days 1–3). The patient received four cycles of platinum-based doublet chemotherapy combined with PD-L1 inhibitor. Following two cycles of chemotherapy and PD-L1 inhibitor treatment, the patient’s tumor shrank significantly. After the 4 cycles of therapy, the patient was given PD-L1 inhibitor every 3-week as maintenance. PR was achieved, the mediastinal and neck tumor significantly shrank, pleural effusion disappeared, and only one lesion remained in the left lower lobe (). The patient’s symptoms of a cough, chest tightness, and asthma disappeared, and his quality of life improved significantly, with moderate adverse events. A CT scan of the patient’s chest indicated that the pulmonary lesions were stable ().

Figure 1

Chest CT scan at baseline.

Figure 2

IHC staining for PD-1, PD-L1, and CD8+. (A) IHC positivity for PD-1 on TILs (10×); (B) IHC negative for PD-L1 on tumor cells (10×); (C) IHC negative for PD-L1 on tumor cells (40×); (D) IHC negative for CD8+ on TILs (10×). IHC, immunohistochemistry; PD-1/L1, programmed death receptor-1/ligand 1.

Figure 3

Chest CT scan after two cycles of chemotherapy combined with PD-L1 inhibitor. PD-L1, programmed death receptor ligand 1.

Figure 4

PD-L1 inhibitor as maintenance treatment. PD-L1, programmed death receptor ligand 1.

A CT scan of the patient’s chest on September 28, 2018 showed a mass in the left lung, with enlarged mediastinal and left hilum lymph nodes, and left pleural effusion.

A CT scan of the patient’s chest on November 12, 2018 showed that the tumor and the mediastinal node lymph nodes had shrunk significantly and pleural effusion had disappeared.

The chest CT scan on November 12, 2018 showed that the tumor in the left lower lobe was stable.

Review of literature

The biological characteristics of SCLC and perspectives of immunotherapy in SCLC

TMB is considered to be a predictive biomarker for ICI therapy in cancer treatment (9). Due to its genomic instability and high mutagenicity, SCLC is extremely heterogeneous. In previous studies on SCLC, a series of high-frequency inactivation mutations of tumor suppressor genes were found; these included TP53 (75–90%) (10), RB1 (60–90%) (11,12), PTEN (2–4%) (13), and activation mutations of the oncogenes PIK3CA, EGFR, and KRAS (14-16). In addition, there was the MYC gene family, EGFR/BCL2 gene amplification and RASSFIA/PTEN/Fhit gene deficiency (17). The majority of SCLC patients mostly have been exposed to tobacco, the carcinogenic effect of which is associated with a higher mutational burden. In whole genome sequencing of NCI-H209, an SCLC cell line, 22 somatic cells acquired replacements, 65 inserts, and deletions, 58 structural variations were detected. In the mutation of the genomic encoding region, as well as in the MLL2 gene, RB1 C706 mutations and destructive mutations of TP53 gene shear position were found (18).

It is likely that SCLC patients have the immunosuppressive phenotype, despite the high rate of somatic tumor mutation. In previous studies, major histocompatibility antigen class I (MHC-I), which potentially rendered patients more sensitive to immune response, was found to be down-regulated in SCLC (19). A decrease or loss of MHC-I expression results in a decrease in antigen presentation to cytotoxic T cells (CTLs), which allows SCLC cells to evade tumor immune response and develop resistance to ICIs. Furthermore, in SCLC, major histocompatibility antigen class II (MHC-II) and immature myeloid cells are not expressed, making patients more likely to have no immune response (20). In summary, low expression of MHC antigens is a negative predictor of immunotherapy response.

The anti-PD-1/PD-L1 pathway

Part of the CD28 immunoglobulin superfamily, PD-1 is a negative co-stimulating molecule which is usually expressed by CD4/CD8 T cells, dendritic cells, B cells, monocytes, and natural killer T cells. PD-L1 (B7-H1), the most important ligand of PD-1. It is a member of the B7 superfamily, which is expressed on the surface of immune cells and epithelial cells. Combined application of PD-1 and PD-L1 can inhibit the activation and proliferation of T cells, trigger T cell apoptosis, induce and maintain immune tolerance and escape of tumor immune (21). Therefore, blocking the PD-1/PD-L1 signal can promote immune response (22).

Nivolumab

By preventing PD-1 from interacting with PD-L1/PD-L2, nivolumab induces an antitumor immune response. In 2014, the food and drug administration (FDA) approved the use of nivolumab for the treatment of advanced melanoma patients. It had been previously approved for the treatment of metastatic NSCLC. Two phase III trials showed that nivolumab held greater benefits in terms of survival than docetaxel. In 2015, the FDA also approved nivolumab for treating advanced or metastatic squamous cells (23,24).

Treatment for the PD-1/PD-L1 axis was first reported in a multi-cohort study which included SCLC. In the study Checkmate-032, 216 SCLC patients with unknown PD-L1 status were divided into three different cohorts. In the single-agent cohort, the objective RR was 11.9% and 17.2% of patients showed no progress at 6 months. OS at 12 and 18 months was 28.3% and 20.0%, respectively. The incidence of grade 3–4 treatment-related adverse events was 11.9%. Three patients (2.8%) discontinued in the study due to treatment-related adverse events. Nivolumab was found to have long-lasting efficacy and good tolerance in the treatment of recurrent SCLC (25).

Checkmate 451, a phase III randomized double-blind study, enrolled approximately 810 patients with ES-SCLC. The primary endpoints included OS and PFS, and the results have not yet been published (26).

Checkmate 331, an ongoing study, aims to compare nivolumab monotherapy versus chemotherapy as a second-line therapy for 480 patients with relapsed SCLC whose disease progressed after prior advance treatment in the phase III open-label randomized trial. The primary endpoint is OS and the results have not been published yet (27).

Pembrolizumab

The FDA approved pembrolizumab to treat metastatic or inoperable melanoma in 2014. Recently, pembrolizumab has also been used to benefit lung cancer patients who got progressed disease after first-line chemotherapy and those with ALK rearrangement or EGFR positive mutation lung cancer who were progressed after targeted therapy.

Keynote-604 enrolled 453 patients with ES-SCLC in phase III randomized, double-blind placebo-controlled trial to detected first-line pembrolizumab with 4 cycles of chemotherapy until PD was reported. The primary endpoints were PFS and OS. The study is ongoing and will be published in 2020 (28).

Many other first-line SCLC trials have also studied the effects of pembrolizumab. Phase I Keynote-011 used pembrolizumab in combination with standard chemotherapy to treat SCLC. The results will be published in 2020. Phase II clinical trial REACTION was an open, multi-center, randomized controlled trial which compared the efficacy of chemotherapy in combination with pembrolizumab or placebo. PFS was the primary endpoint. Preliminary results will be published in 2020.

NCI-2015-00107 was a phase II trial for single-arm maintenance of pembrolizumab in ES-SCLC. The primary endpoint was PFS. The median PFS was 1.4 months, and the 1-year PFS was 13%. The expression of PD-L1 in tumor stroma was detected in 20/30 cases. The median PFS in patients with positive PD-L1 expression in tumor interstitial interface was 6.5 months. In contrast, the median PFS in patients with negative PD-L1 expression in tumor interstitial interface was 1.3 months. Overall, maintaining pembrolizumab did not improve PFS. However, the 1-year PFS and OS rates were 13% and 37%, respectively. This suggests that some patients could benefit from treatment with pembrolizumab (29).

Keynote-028 studied the effects of pembrolizumab on SCLC. This study only recruited PD-L1 positive (>1%) patients. Twenty-four ES-SCLC patients with at least one previous platinum treatment were treated with pembrolizumab. The overall response rate (ORR) was 33%. In this cohort, the median reaction duration was 19.4 months. The median OS was 9.7 months and the 12-month OS rate was close to 40%. Pembrolizumab is awaiting larger trials for its use as a single-agent treatment in second-line therapy.

Keynote-158 enrolled 107 ES-SCLC patients who received pembrolizumab as a second-line therapy. The primary endpoints were ORR. DOR and PFS. Forty-two (39%) cases were PD-L1 positive and 50 (47%) cases were PD-L1 negative. ORR was 18.7%. In general, the median DOR was not reached. Twelve patients (77%) had DOR ≥9 months. The median PFS of all patients was 2.0 months. The median PFS of PD-L1 positive and PD-L1 negative patients was 2.1 and 1.9 months, respectively. In this study, pembrolizumab exhibited significant antitumor activity and had a sustained response in SCLC, particularly amongst tumor PD-L1 positive expression patients (30).

Atezolizumab

Atezolizumab is a monoclonal antibody against IgG1 isotype of PD-L1. Atezo-monotherapy has shown good safety and efficacy in many tumor types. Preclinical and phase I data suggests that atezolizumab may have synergistic effects, leading to long-lasting responses in NSCLC when used alongside platinum-based chemotherapy.

IMPOWER 133 included 403 patients with ES-SCLC. The study was a phase I/III trial which evaluated the efficacy and safety of the first-line atezolizumab when used in combination with chemotherapy. The primary endpoints were PFS and OS. The median OS was 12.3 months in the atezolizumab arm versus 10.3 months in the placebo arm. The median PFS was 5.2 months in the atezolizumab group versus 4.3 months in the placebo group. Studies showed that in the first-line treatment of ES-SCLC, atezolizumab used in combination with chemotherapy could significantly improve survival (8,31).

Fct-1603 was a phase II study compared Atezolizumab with chemotherapy. In this study, 73 SCLC patients were randomized to Atezolizumab and chemotherapy. The primary endpoint was ORR at 6 weeks, the secondary endpoint was PFS. PFS was 1.4 months with Atezolizumab and 4.2 months with chemotherapy, respectively. The screening biomarker was PD-L1 (32). There was no efficacy or safety of Atezolizumab in recurrent SCLC. Follow-up data will be updated.

Durvalumab

Durvalumab is cancer immunotherapy developed by MedImmune/AstraZeneca, which blocks PD-L1 with PD-1 and CD80 (B7.1). It demonstrated a certain degree of safety and clinical activity when used before the initial treatment of SCLC patients and was studied in CASPIAN, a phase III, randomized trial.

The anti-CTLA-4 pathway

CTLA-4 inhibitors currently include tremelimumab and ipilimumab, the latter being the earliest agent to be used as a clinical ICI, as approved by the FDA.

Ipilimumab

Ipilimumab can effectively block the binding of CTLA-4 to its ligand. It was reported that the irPFS and PFS of patients with lung cancer treated by phased ipilimumab combined with paclitaxel and carboplatin showed improvements. This supports the call for further research into ipilimumab in NSCLC.

Ca184-156 was a phase III randomized double-blind study to evaluate the safety and efficacy of ipilimumab or placebo when used in combination with chemotherapy to treat newly diagnosed ES-SCLC. In this study, 1,132 patients were recruited and randomized (33).

Tremelimumab

CASPIAN was a phase III randomized, multicenter, open-label study, which was designed to assess the efficacy of Durvalumab or Tremelimumab and Durvalumab in combination with chemotherapy. The main endpoints included PFS and OS, and the results are pending (34).

Conclusions

For decades, there has been no substantial progress in the treatment of SCLC, and previous trials have shown that immunotherapy with checkpoint inhibitors may be an effective way to control disease over the long term. Although combination therapy is more effective, therapeutic toxicity must also be considered, particularly in SCLC patients outside of clinical trials, who are typically in a poor ECOG state. Therefore, determining which patients could benefit from immunotherapy remains an important research objective. Although early results have suggested that high TMB and positive expression of PD-L1 may be conducive to the selection of CTLA-4/PD-1 inhibitor combination, no consensus has been reached and more relevant evidence is required. The results of the large phase III trial currently underway are eagerly awaited.

The article’s supplementary files as